Provider: View Press Release
Type: Link
Title: GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients | GSK
Description: GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA
Provider: View Press Release
Type: Link
Title: GSK announced as a Principal Partner of COP26 UN Climate Change Conference | GSK
Description: As Principal Partner, GSK will drive action on climate, nature and health targets in support of COP26 ambitions.
Provider: View Press Release
Type: Link
Title: EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19 | GSK
Description: Opinion based on the EMA’s CHMP review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19.
Provider: View Press Release
Type: Link
Title: GSK announces sale of stake in Innoviva Inc | GSK
Description: Shares to be sold back to Innoviva at $12.25 per share
Provider: View Press Release
Type: Link
Title: Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate | GSK
Description: Neutralizing antibody responses were ten times higher than in people recovering from COVID-19.
Provider: View Press Release
Type: Link
Title: Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial | GSK
Description: Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups.